{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:06:37Z","timestamp":1763816797033,"version":"3.45.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institute of Health","doi-asserted-by":"publisher","award":["K23-AI177939","R01-AI143453"],"award-info":[{"award-number":["K23-AI177939","R01-AI143453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR134342","NIHR303140"],"award-info":[{"award-number":["NIHR134342","NIHR303140"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013986","name":"UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cryptococcosis remains a major cause of mortality in people with HIV (PWH). While glucuronoxylomannan-binding immunoglobulin G (GXM-IgG) levels have been associated with disease status and survival, the clinical significance of glucuronoxylomannogalactan-binding IgG (GXMGal-IgG) has not been investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed serological data from 2 previously reported cohorts of PWH: a prospective asymptomatic South African cohort (67 cryptococcal antigen [CrAg] positive, 130 CrAg negative), and a Vietnamese case-control cohort (30 with symptomatic cryptococcal meningitis [CM], 30 without), both followed for mortality for 6 months. Serum\/plasma GXMGal-IgG levels were quantified by enzyme-linked immunosorbent assay and compared to previously reported GXM-IgG levels. Logistic regression adjusted for age, sex, and CD4 count examined associations between antibody levels and CrAg positivity or CM status, while Cox proportional hazards models adjusted for CD4 count estimated associations with time to mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher GXMGal-IgG was associated with CrAg positivity (odds ratio, 1.64; 95% confidence interval [CI], 1.14\u20132.36), not CM status. Among individuals with asymptomatic cryptococcal antigenemia, higher GXMGal-IgG trended toward higher survival (hazards ratio, 0.67; 95% CI, .41\u20131.09), but this was not statistically significant and no significant survival benefit was observed for those with CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GXMGal-IgG was associated with CrAg positivity and showed a modest trend toward survival for individuals with asymptomatic cryptococcal antigenemia but had limited predictive value for CM or mortality. These findings in antigenemia largely parallel previous observations for GXM-IgG, although associations observed were generally weaker. Further studies are needed to clarify the immune response to GXMGal and its potential diagnostic or prognostic significance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf366","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:36:15Z","timestamp":1751960175000},"page":"1220-1227","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV"],"prefix":"10.1093","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-6876","authenticated-orcid":false,"given":"Hyunah","family":"Yoon","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio S","family":"Nakouzi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York ,","place":["USA"]},{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel M","family":"Wake","sequence":"additional","affiliation":[{"name":"Wits Mycology Division, Faculty of Health Sciences , University of the Witwatersrand, Johannesburg ,","place":["South Africa"]},{"name":"Institute for Infection and Immunity, City St George's, University of London , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology and Infection, Royal Devon and Exeter University Hospital NHS Trust , Exeter ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-1690","authenticated-orcid":false,"given":"Caroline T","family":"Tiemessen","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg ,","place":["South Africa"]},{"name":"Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelesh P","family":"Govender","sequence":"additional","affiliation":[{"name":"Wits Mycology Division, Faculty of Health Sciences , University of the Witwatersrand, Johannesburg ,","place":["South Africa"]},{"name":"Institute for Infection and Immunity, City St George's, University of London , London ,","place":["United Kingdom"]},{"name":"MRC Centre for Medical Mycology at the University of Exeter , Exeter ,","place":["United Kingdom"]},{"name":"Division of Medical Microbiology, Faculty of Health Sciences , University of Cape Town, Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-5554","authenticated-orcid":false,"given":"Joseph N","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine , London ,","place":["United Kingdom"]},{"name":"Botswana Harvard Health Partnership , Gaborone ,","place":["Botswana"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7953-6948","authenticated-orcid":false,"given":"Elias Barbosa","family":"da Silva-Junior","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-3657","authenticated-orcid":false,"given":"Israel","family":"Diniz-Lima","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Decote-Ricardo","sequence":"additional","affiliation":[{"name":"Instituto de Veterin\u00e1ria, Universidade Federal Rural do Rio de Janeiro , Serop\u00e9dica ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Osvaldo","family":"Previato","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Mendon\u00e7a-Previato","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S","family":"Harrison","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, City St George's, University of London , London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celio Geraldo","family":"Freire-de-Lima","sequence":"additional","affiliation":[{"name":"Instituto de Biof\u00edsica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-2961","authenticated-orcid":false,"given":"Liise-anne","family":"Pirofski","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York ,","place":["USA"]},{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025112208030680200_jiaf366-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2025112208030680200_jiaf366-B2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0966-842X(00)01890-4","article-title":"How does Cryptococcus get its coat?","volume":"8","author":"Doering","year":"2000","journal-title":"Trends Microbiol"},{"key":"2025112208030680200_jiaf366-B3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/CDLI.5.2.146-159.1998","article-title":"Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network","volume":"5","author":"Cherniak","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"2025112208030680200_jiaf366-B4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciac633","article-title":"Association of antibody immunity with cryptococcal antigenemia and mortality in a South African cohort with advanced human immunodeficiency virus disease","volume":"76","author":"Yoon","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025112208030680200_jiaf366-B5","doi-asserted-by":"crossref","first-page":"ofy333","DOI":"10.1093\/ofid\/ofy333","article-title":"Antibody responses in HIV-infected patients with advanced immunosuppression and asymptomatic cryptococcal antigenemia","volume":"6","author":"Hlupeni","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025112208030680200_jiaf366-B6","doi-asserted-by":"crossref","first-page":"myad102","DOI":"10.1093\/mmy\/myad102","article-title":"Shared and unique antibody and B cell profiles in HIV-positive and HIV-negative individuals with cryptococcal meningoencephalitis","volume":"61","author":"Yoon","year":"2023","journal-title":"Med Mycol"},{"key":"2025112208030680200_jiaf366-B7","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1128\/iai.64.9.3446-3450.1996","article-title":"Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies","volume":"64","author":"Zhong","year":"1996","journal-title":"Infect Immun"},{"key":"2025112208030680200_jiaf366-B8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4049\/jimmunol.166.2.1087","article-title":"A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection","volume":"166","author":"Fleuridor","year":"2001","journal-title":"J Immunol"},{"key":"2025112208030680200_jiaf366-B9","first-page":"582","article-title":"Distribution of the O-acetyl groups and \u03b2-galactofuranose units in galactoxylomannans of the opportunistic fungus Cryptococcus neoformans","volume":"27","author":"Previato","year":"2017","journal-title":"Glycobiology"},{"key":"2025112208030680200_jiaf366-B10","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1074\/jbc.M509465200","article-title":"The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction","volume":"281","author":"McFadden","year":"2006","journal-title":"J Biol Chem"},{"key":"2025112208030680200_jiaf366-B11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1128\/EC.00268-09","article-title":"Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable","volume":"9","author":"De Jesus","year":"2010","journal-title":"Eukaryot Cell"},{"key":"2025112208030680200_jiaf366-B12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fmed.2019.00129","article-title":"Immunomodulatory role of capsular polysaccharides constituents of Cryptococcus neoformans","volume":"6","author":"Decote-Ricardo","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2025112208030680200_jiaf366-B13","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.4049\/jimmunol.0900449","article-title":"Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage","volume":"183","author":"De Jesus","year":"2009","journal-title":"J Immunol"},{"key":"2025112208030680200_jiaf366-B14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/imt.11.86","article-title":"Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy","volume":"3","author":"Vecchiarelli","year":"2011","journal-title":"Immunotherapy"},{"key":"2025112208030680200_jiaf366-B15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1462-5822.2005.00619.x","article-title":"Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8","volume":"8","author":"Pericolini","year":"2006","journal-title":"Cell Microbiol"},{"key":"2025112208030680200_jiaf366-B16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/iai.65.1.272-278.1997","article-title":"Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells","volume":"65","author":"Chaka","year":"1997","journal-title":"Infect Immun"},{"key":"2025112208030680200_jiaf366-B17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/j.1462-5822.2008.01125.x","article-title":"Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand","volume":"10","author":"Villena","year":"2008","journal-title":"Cell Microbiol"},{"key":"2025112208030680200_jiaf366-B18","doi-asserted-by":"crossref","first-page":"16378","DOI":"10.1038\/s41598-018-34649-4","article-title":"Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection","volume":"8","author":"LaRocque-de-Freitas","year":"2018","journal-title":"Sci Rep"},{"key":"2025112208030680200_jiaf366-B19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.4049\/jimmunol.131.3.1455","article-title":"Antibody-dependent leukocyte killing of Cryptococcus neoformans","volume":"131","author":"Miller","year":"1983","journal-title":"J Immunol"},{"key":"2025112208030680200_jiaf366-B20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/247148a0","article-title":"Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells","volume":"247","author":"Diamond","year":"1974","journal-title":"Nature"},{"key":"2025112208030680200_jiaf366-B21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/iai.51.2.556-562.1986","article-title":"Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans","volume":"51","author":"Nabavi","year":"1986","journal-title":"Infect Immun"},{"key":"2025112208030680200_jiaf366-B22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4049\/jimmunol.94.6.916","article-title":"Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection","volume":"94","author":"Bennett","year":"1965","journal-title":"J Immunol"},{"key":"2025112208030680200_jiaf366-B23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1128\/iai.55.3.749-752.1987","article-title":"Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody","volume":"55","author":"Dromer","year":"1987","journal-title":"Infect Immun"},{"key":"2025112208030680200_jiaf366-B24","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/cid\/ciz485","article-title":"Cryptococcal-related mortality despite fluconazole preemptive treatment in a cryptococcal antigen screen-and-treat program","volume":"70","author":"Wake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025112208030680200_jiaf366-B25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/cid\/cix872","article-title":"High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients","volume":"66","author":"Wake","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025112208030680200_jiaf366-B26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0008-6215(97)10058-1","article-title":"Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67","volume":"306","author":"Vaishnav","year":"1998","journal-title":"Carbohydr Res"},{"key":"2025112208030680200_jiaf366-B27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0065-2164(09)01204-0","article-title":"The capsule of the fungal pathogen Cryptococcus neoformans","volume":"68","author":"Zaragoza","year":"2009","journal-title":"Adv Appl Microbiol"},{"key":"2025112208030680200_jiaf366-B28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/EC.00331-08","article-title":"Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan","volume":"8","author":"Jesus","year":"2009","journal-title":"Eukaryot Cell"},{"key":"2025112208030680200_jiaf366-B29","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.3390\/app12147086","article-title":"Cryptococcus: history, epidemiology and immune evasion","volume":"12","author":"Diniz-Lima","year":"2022","journal-title":"Appl Sci"},{"key":"2025112208030680200_jiaf366-B30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fmicb.2011.00181","article-title":"Multiple disguises for the same party: the concepts of morphogenesis and phenotypic variations in Cryptococcus neoformans","volume":"2","author":"Zaragoza","year":"2011","journal-title":"Front Microbiol"},{"key":"2025112208030680200_jiaf366-B31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/cid\/cir613","article-title":"Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis","volume":"53","author":"Jarvis","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025112208030680200_jiaf366-B32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.carres.2009.03.003","article-title":"The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid","volume":"344","author":"Heiss","year":"2009","journal-title":"Carbohydr Res"},{"key":"2025112208030680200_jiaf366-B33","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1128\/IAI.00111-10","article-title":"Immunomodulatory effects of serotype B glucuronoxylomannan from Cryptococcus gattii correlate with polysaccharide diameter","volume":"78","author":"Fonseca","year":"2010","journal-title":"Infect Immun"},{"key":"2025112208030680200_jiaf366-B34","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/13693780902788621","article-title":"The still obscure attributes of cryptococcal glucuronoxylomannan","volume":"47","author":"Rodrigues","year":"2009","journal-title":"Med Mycol"},{"key":"2025112208030680200_jiaf366-B35","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/CVI.05052-11","article-title":"Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen","volume":"18","author":"Percival","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2025112208030680200_jiaf366-B36","doi-asserted-by":"crossref","first-page":"e2016198118","DOI":"10.1073\/pnas.2016198118","article-title":"A glycan FRET assay for detection and characterization of catalytic antibodies to the Cryptococcus neoformans capsule","volume":"118","author":"Crawford","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112208030680200_jiaf366-B37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/infdis\/165.6.1086","article-title":"Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection","volume":"165","author":"Casadevall","year":"1992","journal-title":"J Infect Dis"},{"key":"2025112208030680200_jiaf366-B38","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4161\/viru.1.6.13451","article-title":"Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans","volume":"1","author":"Jesus","year":"2010","journal-title":"Virulence"},{"key":"2025112208030680200_jiaf366-B39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nri2524","article-title":"B cells in HIV infection and disease","volume":"9","author":"Moir","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2025112208030680200_jiaf366-B40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0923-2494(90)90099-K","article-title":"An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan","volume":"141","author":"van de Moer","year":"1990","journal-title":"Res Immunol"},{"key":"2025112208030680200_jiaf366-B41","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.vaccine.2010.12.134","article-title":"Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis","volume":"29","author":"Chow","year":"2011","journal-title":"Vaccine"},{"key":"2025112208030680200_jiaf366-B42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2025112208030680200_jiaf366-B43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/AAC.43.2.233","article-title":"Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations","volume":"43","author":"Nosanchuk","year":"1999","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf366\/63705115\/jiaf366.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/5\/1220\/63705115\/jiaf366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/232\/5\/1220\/63705115\/jiaf366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:03:22Z","timestamp":1763816602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/232\/5\/1220\/8193923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf366","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,7,8]]}}}